This really sucks.
Quick takes: Novavax COVID vaccine effectiveness, COVID booster uptake, avian flu in two states | CIDRAP
Quick takes: Novavax COVID vaccine effectiveness, COVID booster uptake, avian flu in two states
An observational study following the rollout of the Novavax’s protein-based adjuvanted COVID vaccine in Italy found that protection against symptomatic disease was 50% in fully vaccinated people, with an estimated effectiveness of 31% in all notified cases, researchers reported yesterday in JAMA Network Open. Over a 4-month period, effectiveness waned against infection but was stable against symptomatic disease. The study took place in Italy in more than 20,000 adults between February 28, 2022, and September 2022, a time when the Omicron variant was dominant.
Quick takes: Novavax COVID vaccine effectiveness, COVID booster uptake, avian flu in two states | CIDRAP
Quick takes: Novavax COVID vaccine effectiveness, COVID booster uptake, avian flu in two states
An observational study following the rollout of the Novavax’s protein-based adjuvanted COVID vaccine in Italy found that protection against symptomatic disease was 50% in fully vaccinated people, with an estimated effectiveness of 31% in all notified cases, researchers reported yesterday in JAMA Network Open. Over a 4-month period, effectiveness waned against infection but was stable against symptomatic disease. The study took place in Italy in more than 20,000 adults between February 28, 2022, and September 2022, a time when the Omicron variant was dominant.